OTTAWA, June 14, 2012 /CNW/ - BIOQuébec and Canada's Research-Based Pharmaceutical Companies (Rx&D) today signed a partnership agreement aimed at reinforcing the linkages
and alignment between the biotechnology and pharmaceutical associations
in support of life science research in Quebec.
The partnership between the two associations builds on the progress made
at the Forum des sciences de la vie held in Montreal on June 1st. Working together, BIOQuébec and Rx&D will help strengthen Quebec's position as a leader in developing and
delivering new health care solutions.
"BIOQuébec and Rx&D share the same objective to ensure the vitality of
the Quebec life sciences industry and the growth of its businesses,
corporations and organizations. The partnership agreement between the
two organizations reaffirms this commitment and reflects the shared
determination to contribute to the development of this sector,
considered a jewel of the Quebec economy" according to Mario Lebrun,
BIOQuebec's Director General.
"What excites me the most about this partnership is that it is an
excellent example of how collaboration can further enhance Quebec's
research capacity and contribute to the growth of the knowledge economy
of the province," said Russell Williams, President of Rx&D. "Formalizing the relationship between BIOQuébec and Rx&D is an important signal of progress in this new era of pharmaceutical
and biopharmaceutical research," added Mr. Williams.
BIOQuébec is a biotechnology and life science industry association
representing nearly 100 member companies and R&D centers in Quebec. The association works to create a positive
influence on the growth of the life science industry, including capital
access, public policy, workforce development and international
Rx&D is the association of leading research-based pharmaceutical
companies dedicated to improving the health of Canadians through the
discovery and development of new medicines and vaccines. Our community
represents 15,000 men and women working for 50 member companies and
invests more than $1 billion in research and development each year to
fuel Canada's knowledge-based economy. Guided by our Code of Ethical
Practices, our membership is committed to working in partnership with
governments, healthcare professionals and stakeholders in a highly
SOURCE CANADA'S RESEARCH-BASED PHARMACEUTICAL COMPANIES (RX
For further information: